In May 2012, Baylor College of Medicine (BCM) announced that they will receive up to $6.2 million over five years from the National Institute Of Allergy and Infectious Diseases, to develop a vaccine for severe acute respiratory syndrome (SARS). The research and development will be done in partnership with the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development.
Vaccines in the past have actually exacerbated the SARS infection. Sabin’s recombinant RBD-S SARS vaccine will work to get around the problem by stimulating neutralizing antibodies to block the attachment of the virus to its receptor. The vaccine would be used to prevent potential SARS outbreaks as well as for biodefense preparedness.